Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells
Authors
Keywords
TRAIL, Liposome, Leukemia, Immunotherapy, TRAIL resistance
Journal
Clinical & Translational Oncology
Volume 17, Issue 8, Pages 657-667
Publisher
Springer Nature
Online
2015-05-12
DOI
10.1007/s12094-015-1295-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immuno-LipoTRAIL: Targeted Delivery of TRAIL-Functionalized Liposomal Nanoparticles
- (2014) Oliver Seifert et al. BIOCONJUGATE CHEMISTRY
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib
- (2014) M. Loi et al. JOURNAL OF CONTROLLED RELEASE
- Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia
- (2014) C Reynolds et al. LEUKEMIA
- TRAIL-coated leukocytes that kill cancer cells in the circulation
- (2014) M. J. Mitchell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
- (2014) P Geserick et al. Cell Death & Disease
- Death receptors as targets in cancer
- (2013) O Micheau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation
- (2013) Laura Vela et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
- (2013) Diego De Miguel et al. MOLECULAR PHARMACEUTICS
- State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
- (2012) Stella Bernardi et al. Recent Patents on Anti-Cancer Drug Discovery
- The therapeutic potential of TRAIL receptor signalling in cancer cells
- (2011) Rosario Yerbes et al. Clinical & Translational Oncology
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis
- (2010) Luis Martinez-Lostao et al. ARTHRITIS AND RHEUMATISM
- Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells
- (2010) Nuria López-Royuela et al. BIOCHEMICAL PHARMACOLOGY
- BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia
- (2010) Nan Jiang et al. EXPERIMENTAL HEMATOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
- (2008) Patricia Balsas et al. BIOCHEMICAL PHARMACOLOGY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started